At Graftys, we develop, manufacture, and commercialize synthetic bone graft substitute, which have very similar chemical composition with natural bone, making it ideal for bone healing and regeneration.
Graftys’ products are registered in more than 30 countries worldwide.
More than 80,000 units of injectable implanted since their launch.
More than 100 scientific papers about Graftys’s products and technologies have been publsihed on different prominent orthopedic journals and newspapers.
Graftys is devoted to bringing safe, efficient, innovative, and ergonomic bone void fillers for patients, orthopedic surgeons, and hospitals, addressing the unmet need for those who suffer from bone diseases and traumatic injury, improving the quality of patients’ life.
Here at Graftys, we find that our company values are highly important to us. We have established our team according to preselected competences which fit our company’s DNA. We believe our company’s culture has an influence on productivity, creativity and overall profitability.
GMP Brazil (ANVISA) – granted Nov. 2018 + GMP surveillance audits (2020)
Re-certifications injectables (Quickset & HBS) & ancillaries (Europe) – granted May 2020
Re-registration Brazil (ANVISA) – granted Nov. 2018
MDSAP (Australia, Canada) – granted Feb. 2020
As Chief Executive Officer and member of executive board, Aurélien brings fifteen years of cross-functional leadership experience in Orthobiologics industry. Prior to joining Graftys in Nov 2021, he served as CEO & President of Biologics 4 life, leading the company’s acquisition and integration by Graftys. Before his time at bio4life, he served as CEO of Graftys where he was responsible for overseeing the development and commercialization of their innovative injectable bone grafts, successfully achieving several regulatory approvals (510k, CE, ANVISA…) and driving the companys’ peak revenue growth until Graftys’ acquisition end of 2017. He holds a, executive MBA from Kedge Business School.
As Chief Operating Officer and member of executive board, Sébastien is responsible for developing and executing product dev. strategy and growth initiatives for Graftys. He joined Graftys team in Nov 2021 after spending 3.5 years as Chief Operating and Dev. Officer at Biologics 4 life, a Medtech company he co-founded with Biologics4Life CEO Aurelien Valet. He brings 15 years of successful business experience in Sales, Supply Chain, Medtech and Biotech industries. Sébastien holds Masters of Science degree in Genomics from AMU, in management from IAE and an executive M.B.A. from Kedge Business school.
As Chief Financial Officer and member of executive board director of Graftys, Xavier is responsible for the group’s global finances, investor relations and controllership. He joined the Graftys team in Nov 2021 after spending 2.5 years as CFO at Biologics 4 life, where he played a major role in the M&A operation with Graftys. Xavier brings fifteen years of experience as CFO and a seasoned investor in Medtech startups (in which he successfully sold 20 companies). He holds a phD in Pharmacology and a Master of Science in Management.
Leave us a note and we will get back to you as soon as possible.